{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:47:52Z","timestamp":1792154872661,"version":"4.4.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05160-2","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:07:26Z","timestamp":1784635646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction\u2013associated steatotic liver disease: a meta-analysis (2015\u20132025)"],"prefix":"10.1186","volume":"26","author":[{"given":"Muteia\u2019a","family":"Hamood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8199-6098","authenticated-orcid":false,"given":"Mohammed Ahmed","family":"Al-Salehi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali F.","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid Mohammed","family":"Naji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"5160_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.017.","journal-title":"J Hepatol"},{"key":"5160_CR2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jhep.2023.05.003","volume":"79","author":"A call for unity","year":"2023","unstructured":"A call for unity. The path towards a more precise and patient-centric nomenclature for NAFLD. J Hepatol. 2023;79:4\u20135. https:\/\/doi.org\/10.1016\/j.jhep.2023.05.003.","journal-title":"J Hepatol"},{"key":"5160_CR3","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202\u20139. https:\/\/doi.org\/10.1016\/j.jhep.2020.03.039.","journal-title":"J Hepatol"},{"key":"5160_CR4","doi-asserted-by":"publisher","unstructured":"Gofton C, Upendran Y, Zheng M-H, George J. Suppl. S17\u201331. https:\/\/doi.org\/10.3350\/cmh.2022.0367.","DOI":"10.3350\/cmh.2022.0367"},{"key":"5160_CR5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.312","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J. International consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999\u20132014.e1. https:\/\/doi.org\/10.1053\/j.gastro.2019.11.312.\u00a0"},{"key":"5160_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1159\/000538301","volume":"13","author":"BG Song","year":"2024","unstructured":"Song BG, Kim A, Goh MJ, Kang W, Gwak G-Y, Paik Y-H, et al. Risk of hepatocellular carcinoma by steatotic liver disease and its newly proposed subclassification. Liver Cancer. 2024;13:561\u201371. https:\/\/doi.org\/10.1159\/000538301.","journal-title":"Liver Cancer"},{"key":"5160_CR7","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J Hepatol"},{"key":"5160_CR8","doi-asserted-by":"publisher","DOI":"10.1159\/000550163","author":"Y Liu","year":"2025","unstructured":"Liu Y. The Emerging Challenge of Non-Cirrhotic MASLD-related hepatocellular carcinoma: etiology, immunopathology, and precision oncology. Liver Cancer. 2025. https:\/\/doi.org\/10.1159\/000550163.","journal-title":"Liver Cancer"},{"key":"5160_CR9","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23:346. https:\/\/doi.org\/10.1186\/s12933-024-02434-5.","journal-title":"Cardiovasc Diabetol"},{"key":"5160_CR10","doi-asserted-by":"publisher","unstructured":"Xia M, Varmazyad M, Pla-Palac\u00edn I, Gavlock DC, DeBiasio R, LaRocca G, et al. Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy. Front Cell Dev Biol. 2024;12. https:\/\/doi.org\/10.3389\/fcell.2024.1423936.","DOI":"10.3389\/fcell.2024.1423936"},{"key":"5160_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.4254\/wjh.v14.i1.158","volume":"14","author":"J Devi","year":"2022","unstructured":"Devi J, Raees A, Butt AS. Redefining non-alcoholic fatty liver disease to metabolic associated fatty liver disease: is this plausible? World J Hepatol. 2022;14:158\u201367. https:\/\/doi.org\/10.4254\/wjh.v14.i1.158.","journal-title":"World J Hepatol"},{"key":"5160_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2025.06.075","author":"G Sebastiani","year":"2025","unstructured":"Sebastiani G, Raggi P, Guaraldi G. Integrating the care of metabolic dysfunction\u2013associated steatotic liver disease into cardiac rehabilitation: a multisystem approach. Can J Cardiol. 2025. https:\/\/doi.org\/10.1016\/j.cjca.2025.06.075.","journal-title":"Can J Cardiol"},{"key":"5160_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/ueg2.12525","volume":"12","author":"J Zeng","year":"2024","unstructured":"Zeng J, Fan J-G, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United Eur Gastroenterol J. 2024;12:177\u201386. https:\/\/doi.org\/10.1002\/ueg2.12525.","journal-title":"United Eur Gastroenterol J"},{"key":"5160_CR14","doi-asserted-by":"publisher","first-page":"827","DOI":"10.4254\/wjh.v8.i20.827","volume":"8","author":"VV Ravi Kanth","year":"2016","unstructured":"Ravi Kanth VV, Sasikala M, Sharma M, Rao PN, Reddy DN. Genetics of non-alcoholic fatty liver disease: from susceptibility and nutrient interactions to management. World J Hepatol. 2016;8:827\u201337. https:\/\/doi.org\/10.4254\/wjh.v8.i20.827.","journal-title":"World J Hepatol"},{"key":"5160_CR15","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.3390\/nu16081239","volume":"16","author":"M Liu","year":"2024","unstructured":"Liu M, Park S. The role of PNPLA3_rs738409 gene variant, lifestyle factors, and bioactive compounds in nonalcoholic fatty liver disease: a population-based and molecular approach towards healthy nutrition. Nutrients. 2024;16:1239. https:\/\/doi.org\/10.3390\/nu16081239.","journal-title":"Nutrients"},{"key":"5160_CR16","doi-asserted-by":"publisher","first-page":"10054","DOI":"10.3748\/wjg.v21.i34.10054","volume":"21","author":"ZT Liu","year":"2015","unstructured":"Liu ZT, Chen TC, Lu XX, Cheng J, Xie HY, Zhou L, et al. PNPLA3 I148M variant affects non-alcoholic fatty liver disease in liver transplant recipients. World J Gastroenterol. 2015;21:10054\u20136. https:\/\/doi.org\/10.3748\/wjg.v21.i34.10054.","journal-title":"World J Gastroenterol"},{"key":"5160_CR17","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1111\/liv.12909","volume":"35","author":"J-H Park","year":"2015","unstructured":"Park J-H, Cho B, Kwon H, Prilutsky D, Yun JM, Choi HC, et al. I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease. Liver Int. 2015;35:2537\u201346. https:\/\/doi.org\/10.1111\/liv.12909.","journal-title":"Liver Int"},{"key":"5160_CR18","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1097\/MPG.0000000000000662","volume":"60","author":"X Shang","year":"2015","unstructured":"Shang X, Song J, Liu F, Ma J, Wang H. GWAS-Identified common variants with nonalcoholic fatty liver disease in chinese children. J Pediatr Gastroenterol Nutr. 2015;60:669\u201374. https:\/\/doi.org\/10.1097\/MPG.0000000000000662.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5160_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fgene.2016.00140","volume":"7 AUG","author":"X Wang","year":"2016","unstructured":"Wang X, Liu Z, Wang K, Wang Z, Sun X, Zhong L, et al. Additive effects of the risk alleles of PNPLA3 and TM6SF2 on non-alcoholic fatty liver disease (NAFLD) in a Chinese population. Front Genet. 2016;7 AUG:1\u20137. https:\/\/doi.org\/10.3389\/fgene.2016.00140.","journal-title":"Front Genet"},{"key":"5160_CR20","first-page":"60","volume":"6","author":"N Choobini","year":"2016","unstructured":"Choobini N, Azarpira N, Mashayekhi MR. Association of PNPLA3 gene polymorphism (rs738409) and nonalcoholic fatty liver disease in Southern Iranian population. J Adv Biomed Sci. 2016;6:60\u20138.","journal-title":"J Adv Biomed Sci"},{"key":"5160_CR21","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3109\/00365521.2016.1161066","volume":"51","author":"U Vespasiani-Gentilucci","year":"2016","unstructured":"Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, Piccioni L, et al. The PNPLA3 rs738409 C\u2009>\u2009G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol. 2016;51:967\u201373. https:\/\/doi.org\/10.3109\/00365521.2016.1161066.","journal-title":"Scand J Gastroenterol"},{"key":"5160_CR22","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/apt.13521","volume":"43","author":"M-F Xia","year":"2016","unstructured":"Xia M-F, Ling Y, Bian H, Lin H-D, Yan H-M, Chang X-X, et al. I148M variant of PNPLA3 increases the susceptibility to non-alcoholic fatty liver disease caused by obesity and metabolic disorders. Aliment Pharmacol Ther. 2016;43:631\u201342. https:\/\/doi.org\/10.1111\/apt.13521.","journal-title":"Aliment Pharmacol Ther"},{"key":"5160_CR23","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1007\/s10620-016-4120-7","volume":"61","author":"R-N Zhang","year":"2016","unstructured":"Zhang R-N, Zheng R-D, Mi Y-Q, Zhou D, Shen F, Chen G-Y, et al. APOC3 rs2070666 is associated with the hepatic steatosis independently of PNPLA3 rs738409 in Chinese han patients with nonalcoholic fatty liver diseases. Dig Dis Sci. 2016;61:2284\u201393. https:\/\/doi.org\/10.1007\/s10620-016-4120-7.","journal-title":"Dig Dis Sci"},{"key":"5160_CR24","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12664-017-0784-y","volume":"36","author":"S Alam","year":"2017","unstructured":"Alam S, Islam MS, Islam S, Mustafa G, Saleh AA, Ahmad N. Association of single nucleotide polymorphism at PNPLA3 with fatty liver, steatohepatitis, and cirrhosis of liver. Indian J Gastroenterol. 2017;36:366\u201372. https:\/\/doi.org\/10.1007\/s12664-017-0784-y.","journal-title":"Indian J Gastroenterol"},{"key":"5160_CR25","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/MEG.0000000000000813","volume":"29","author":"A Uygun","year":"2017","unstructured":"Uygun A, Ozturk K, Demirci H, Oztuna A, Eren F, Kozan S, et al. The association of nonalcoholic fatty liver disease with genetic polymorphisms: a multicenter study. Eur J Gastroenterol Hepatol. 2017;29:441\u20137. https:\/\/doi.org\/10.1097\/MEG.0000000000000813.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"5160_CR26","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1111\/liv.13478","volume":"37","author":"MA Niriella","year":"2017","unstructured":"Niriella MA, Pathmeswaran A, De Silva ST, Kasturiratna A, Perera R, Subasinghe CE, et al. Incidence and risk factors for non-alcoholic fatty liver disease: A 7-year follow-up study among urban, adult Sri Lankans. Liver Int. 2017;37:1715\u201322. https:\/\/doi.org\/10.1111\/liv.13478.","journal-title":"Liver Int"},{"key":"5160_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00535-017-1372-8","volume":"53","author":"Y Seko","year":"2018","unstructured":"Seko Y, Yamaguchi K, Mizuno N, Okuda K, Takemura M, Taketani H, et al. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease. J Gastroenterol. 2018;53:438\u201348. https:\/\/doi.org\/10.1007\/s00535-017-1372-8.","journal-title":"J Gastroenterol"},{"key":"5160_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-21939-0","volume":"8","author":"A Di Costanzo","year":"2018","unstructured":"Di Costanzo A, Belardinilli F, Bailetti D, Sponziello M, D\u2019Erasmo L, Polimeni L, et al. Evaluation of polygenic determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Sci Rep. 2018;8:1\u201310. https:\/\/doi.org\/10.1038\/s41598-018-21939-0.","journal-title":"Sci Rep"},{"key":"5160_CR29","doi-asserted-by":"publisher","first-page":"e0272","DOI":"10.1097\/MD.0000000000010272","volume":"97","author":"H Yang","year":"2018","unstructured":"Yang H, Chen G, Song C, Li D, Ma Q, Chen G, et al. A novel index including SNPs for the screening of nonalcoholic fatty liver disease among elder Chinese: A population-based study. Med (Baltim). 2018;97:e0272. https:\/\/doi.org\/10.1097\/MD.0000000000010272.","journal-title":"Med (Baltim)"},{"key":"5160_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-019-0992-9","volume":"18","author":"LZ Chen","year":"2019","unstructured":"Chen LZ, Ding HY, Liu SS, Liu Q, Jiang XJ, Xin YN, et al. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China. Lipids Health Dis. 2019;18:1\u20136. https:\/\/doi.org\/10.1186\/s12944-019-0992-9.","journal-title":"Lipids Health Dis"},{"key":"5160_CR31","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/liv.14006","volume":"39","author":"CA Hudert","year":"2019","unstructured":"Hudert CA, Selinski S, Rudolph B, Bl\u00e4ker H, Loddenkemper C, Thielhorn R, et al. Genetic determinants of steatosis and fibrosis progression in paediatric non-alcoholic fatty liver disease. Liver Int. 2019;39:540\u201356. https:\/\/doi.org\/10.1111\/liv.14006.","journal-title":"Liver Int"},{"key":"5160_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jgh.14894","volume":"35","author":"W-Y Liu","year":"2019","unstructured":"Liu W-Y, Zheng KI, Pan X-Y, Ma H-L, Zhu P-W, Wu X-X, et al. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2019;35:1\u20138. https:\/\/doi.org\/10.1111\/jgh.14894.","journal-title":"J Gastroenterol Hepatol"},{"key":"5160_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.aohep.2018.10.004","volume":"18","author":"DF Mazo","year":"2019","unstructured":"Mazo DF, Malta FM, Stefano JT, Salles APM, Gomes-Gouvea MS, Nastri ACS, et al. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Ann Hepatol. 2019;18:466\u201371. https:\/\/doi.org\/10.1016\/j.aohep.2018.10.004.","journal-title":"Ann Hepatol"},{"key":"5160_CR34","first-page":"34","volume":"67","author":"R Karoli","year":"2019","unstructured":"Karoli R, Fatima J, Singh PS, Siddiqi Z, Varshney S, Beg MS, et al. Association of genetic non-alcoholic fatty liver disease with insulin resistance-are we different? J Assoc Physicians India. 2019;67:34\u20138.","journal-title":"J Assoc Physicians India"},{"key":"5160_CR35","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.3390\/ijms20184444","volume":"20","author":"A Di Costanzo","year":"2019","unstructured":"Di Costanzo A, Pacifico L, D\u2019Erasmo L, Polito L, Di Martino M, Perla FM, et al. Nonalcoholic Fatty Liver Disease (NAFLD), But not Its Susceptibility Gene Variants, Influences the Decrease of Kidney Function in Overweight\/Obese Children. Int J Mol Sci. 2019;20:4444. https:\/\/doi.org\/10.3390\/ijms20184444.","journal-title":"Int J Mol Sci"},{"key":"5160_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12664-020-01026-x","volume":"39","author":"A Delik","year":"2020","unstructured":"Delik A, Akk\u0131z H, Din\u00e7er S. The effect of PNPLA3 polymorphism as gain in function mutation in the pathogenesis of non-alcoholic fatty liver disease. Indian J Gastroenterol. 2020;39:84\u201391. https:\/\/doi.org\/10.1007\/s12664-020-01026-x.","journal-title":"Indian J Gastroenterol"},{"key":"5160_CR37","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4254\/wjh.v12.i12.1228","volume":"12","author":"GH Lee","year":"2020","unstructured":"Lee GH, Phyo WW, Loo WM, Kwok R, Ahmed T, Shabbir A, et al. Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population. World J Hepatol. 2020;12:1228\u201338. https:\/\/doi.org\/10.4254\/wjh.v12.i12.1228.","journal-title":"World J Hepatol"},{"key":"5160_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jgm.3160","volume":"22","author":"K Narayanasamy","year":"2020","unstructured":"Narayanasamy K, Karthick R, Panneerselvam P, Mohan N, Ramachandran A, Prakash R, et al. Association of metabolic syndrome and patatin-like phospholipase 3 \u2013 rs738409 gene variant in non-alcoholic fatty liver disease among a Chennai-based south Indian population. J Gene Med. 2020;22:1\u20138. https:\/\/doi.org\/10.1002\/jgm.3160.","journal-title":"J Gene Med"},{"key":"5160_CR39","doi-asserted-by":"publisher","first-page":"792","DOI":"10.4254\/wjh.v12.i10.792","volume":"12","author":"QC Lisboa","year":"2020","unstructured":"Lisboa QC, Nardelli MJ, Pereira P, de Miranda A, Ribeiro DM, Costa SN. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol. 2020;12:792\u2013806. https:\/\/doi.org\/10.4254\/wjh.v12.i10.792.","journal-title":"World J Hepatol"},{"key":"5160_CR40","doi-asserted-by":"publisher","first-page":"e25893","DOI":"10.1097\/MD.0000000000025893","volume":"100","author":"H Akkiz","year":"2021","unstructured":"Akkiz H, Taskin E, Karaogullarindan U, Delik A, Kuran S, Kutlu O. The influence of RS738409 I148M polymorphism of patatin-like phospholipase domain containing 3 gene on the susceptibility of non-alcoholic fatty liver disease. Med (Baltim). 2021;100:e25893. https:\/\/doi.org\/10.1097\/MD.0000000000025893.","journal-title":"Med (Baltim)"},{"key":"5160_CR41","doi-asserted-by":"publisher","DOI":"10.5114\/amscd.2021.105522","author":"M Wawrzynowicz-Syczewska","year":"2021","unstructured":"Wawrzynowicz-Syczewska M, Waszczyk A, Bander D, Mi\u0119tkiewski J, Urba\u0144ska A, Scheibe K. PNPLA3 gene polymorphism and severity of liver steatosis and fibrosis. Clin Res. 2021. https:\/\/doi.org\/10.5114\/amscd.2021.105522.","journal-title":"Clin Res"},{"key":"5160_CR42","doi-asserted-by":"publisher","first-page":"20924","DOI":"10.1038\/s41598-021-00425-0","volume":"11","author":"M Len\u00ed\u010dek","year":"2021","unstructured":"Len\u00ed\u010dek M, \u0160m\u00edd V, Pajer P, Nazarova A, Dvo\u0159\u00e1k K, Subhanov\u00e1 I, et al. Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant. Sci Rep. 2021;11:20924. https:\/\/doi.org\/10.1038\/s41598-021-00425-0.","journal-title":"Sci Rep"},{"key":"5160_CR43","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.3748\/wjg.v27.i25.3863","volume":"27","author":"R-N Zhang","year":"2021","unstructured":"Zhang R-N, Shen F, Pan Q, Cao H-X, Chen G-Y, Fan J-G. PPARGC1A rs8192678 G\u2009>\u2009A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. World J Gastroenterol. 2021;27:3863\u201376. https:\/\/doi.org\/10.3748\/wjg.v27.i25.3863.","journal-title":"World J Gastroenterol"},{"key":"5160_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/metabo12121240","volume":"12","author":"F Alsaif","year":"2022","unstructured":"Alsaif F, Al-hamoudi W, Alotaiby M, Alsadoon A, Almayouf M, Almadany H, et al. Molecular screening via sanger sequencing of the genetic variants in non-alcoholic fatty liver disease subjects in the Saudi population: a hospital-based study. Metabolites. 2022;12:1\u201313. https:\/\/doi.org\/10.3390\/metabo12121240.","journal-title":"Metabolites"},{"key":"5160_CR45","doi-asserted-by":"publisher","unstructured":"Mu T, Peng L, Xie X, He H, Shao Q, Wang X et al. Single nucleotide polymorphism of genes associated with metabolic fatty liver disease. J Oncol. 2022;2022. https:\/\/doi.org\/10.1155\/2022\/9282557.","DOI":"10.1155\/2022\/9282557"},{"key":"5160_CR46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.21608\/ejchem.2022.110164.5055","volume":"65","author":"HM Ragab","year":"2022","unstructured":"Ragab HM, Attaby FA, Abd El Maksoud N, Amin MA, Elhakim A, Abd Elaziz HK. Association between rs738409 and rs139051 SNPs of the PNPLA3 gene and the presence of NAFLD. Egypt J Chem. 2022;65:127\u201337. https:\/\/doi.org\/10.21608\/ejchem.2022.110164.5055.","journal-title":"Egypt J Chem"},{"key":"5160_CR47","doi-asserted-by":"publisher","unstructured":"Maleki S, Sharafi H, Honarvar B, Eslami M, Bagheri Lankarani K, Alavian SM. Association of PNPLA3 rs738409 and TM6SF2 rs58542926 Polymorphisms with Non-alcoholic Fatty Liver Disease in the Iranian Population. Hepat Mon. 2022;22. https:\/\/doi.org\/10.5812\/hepatmon-133330.","DOI":"10.5812\/hepatmon-133330"},{"key":"5160_CR48","doi-asserted-by":"publisher","first-page":"e24626","DOI":"10.1002\/jcla.24626","volume":"36","author":"S Liao","year":"2022","unstructured":"Liao S, An K, Liu Z, He H, An Z, Su Q, et al. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China. J Clin Lab Anal. 2022;36:e24626. https:\/\/doi.org\/10.1002\/jcla.24626.","journal-title":"J Clin Lab Anal"},{"key":"5160_CR49","doi-asserted-by":"publisher","unstructured":"Husseini AA. Genotypic variation in CYP2E1, GCKR, and PNPLA3 among nonalcoholic steatohepatitis patients of Turkish origin. Mol Biol Rep. 2024;51(1):845. https:\/\/doi.org\/10.1007\/s11033-024-09787-w.","DOI":"10.1007\/s11033-024-09787-w"},{"key":"5160_CR50","doi-asserted-by":"publisher","unstructured":"Hegazy MY, Dorgham LS, Elbauomy ASA, Elsabaawy M, Alwarraky M, Tahoon MAH. Genetic insights into metabolic dysfunction-related steatotic liver disease and PNPLA3 variation among Egyptian Population. Menoufia Med J. 2024;38. https:\/\/doi.org\/10.59204\/2314-6788.3306.","DOI":"10.59204\/2314-6788.3306"},{"key":"5160_CR51","doi-asserted-by":"publisher","first-page":"281","DOI":"10.21608\/ajgh.2024.313440.1061","volume":"7","author":"EM Foda","year":"2024","unstructured":"Foda EM, Saleh SAB, Eskandaros MS, El-Khazragy NN, Abu Bakr HM, Massoud YM, et al. Significance of the influence of patatin-like phospholipase domain-containing 3 (PNPLA3) rs738409 polymorphism on non alcoholic fatty liver disease. Afr J Gastroenterol Hepatol. 2024;7:281\u201390. https:\/\/doi.org\/10.21608\/ajgh.2024.313440.1061.","journal-title":"Afr J Gastroenterol Hepatol"},{"key":"5160_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s40009-025-01673-8","author":"V Singh","year":"2025","unstructured":"Singh V, Bag A, Khandelwal B, Sutradhar D. Association of PNPLA3 genetic polymorphism with non-alcoholic fatty liver disease in sikkim: a pilot study. Natl Acad Sci Lett. 2025. https:\/\/doi.org\/10.1007\/s40009-025-01673-8.","journal-title":"Natl Acad Sci Lett"},{"key":"5160_CR53","doi-asserted-by":"publisher","first-page":"102160","DOI":"10.1016\/j.genrep.2025.102160","volume":"38","author":"S Mohamed","year":"2025","unstructured":"Mohamed S, Salum GM, Siddik RI, Elwan SH, Saleh AI, Sweilam H, et al. Evaluation of the association between the PNPLA3 rs738409 variants with the incidence of atherosclerosis in patients with different fatty liver grades. Gene Rep. 2025;38:102160. https:\/\/doi.org\/10.1016\/j.genrep.2025.102160.","journal-title":"Gene Rep"},{"key":"5160_CR54","doi-asserted-by":"publisher","first-page":"201453","DOI":"10.1016\/j.humgen.2025.201453","volume":"45","author":"M Masroor","year":"2025","unstructured":"Masroor M, Haque Z, Anwar H, Hanif F, Farooqui WA. Association of APOC3 and PNPLA3 genetic polymorphism in adult Pakistani population with non-alcoholic fatty liver disease. Hum Gene. 2025;45:201453. https:\/\/doi.org\/10.1016\/j.humgen.2025.201453.","journal-title":"Hum Gene"},{"key":"5160_CR55","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.3390\/ijms26157409","volume":"26","author":"A Arreola Cruz","year":"2025","unstructured":"Arreola Cruz A, Navarro Hern\u00e1ndez JC, Cisneros Garza LE, Miranda Duarte A, Mata Tijerina VL, Hern\u00e1ndez Garcia ME, et al. Contribution of PNPLA3, GCKR, MBOAT7, NCAN, and TM6SF2 Genetic Variants to Hepatocellular Carcinoma Development in Mexican Patients. Int J Mol Sci. 2025;26:7409. https:\/\/doi.org\/10.3390\/ijms26157409.","journal-title":"Int J Mol Sci"},{"key":"5160_CR56","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.12669\/pjms.41.5.11532","volume":"41","author":"B Altaf","year":"2025","unstructured":"Altaf B, Jawed S, Ghazali WSW, Aziz AAA, Salam RMT, Rasheed A, et al. Patatin-like phospholipase domain-containing 3 (PNPLA3) variants rs 738408 and rs 738409 single nucleotide polymorphism as predictor of metabolic associated fatty liver disease and its progression. Pak J Med Sci. 2025;41:1322\u201330. https:\/\/doi.org\/10.12669\/pjms.41.5.11532.","journal-title":"Pak J Med Sci"},{"key":"5160_CR57","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/jgh.12889","volume":"30","author":"L Zhang","year":"2015","unstructured":"Zhang L, You W, Zhang H, Peng R, Zhu Q, Yao A, et al. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol. 2015;30:821\u20139. https:\/\/doi.org\/10.1111\/jgh.12889.","journal-title":"J Gastroenterol Hepatol"},{"key":"5160_CR58","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12902-021-00789-4","volume":"21","author":"N Salari","year":"2021","unstructured":"Salari N, Darvishi N, Mansouri K, Ghasemi H, Hosseinian-Far M, Darvishi F, et al. Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease: a systematic review and meta-analysis. BMC Endocr Disord. 2021;21:125. https:\/\/doi.org\/10.1186\/s12902-021-00789-4.","journal-title":"BMC Endocr Disord"},{"key":"5160_CR59","doi-asserted-by":"publisher","first-page":"e33110","DOI":"10.1097\/MD.0000000000033110","volume":"102","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Zhao W, Ma J, Toshiyoshi M, Zhao Y. Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: a meta-analysis of twenty studies. Med (Baltim). 2023;102:e33110. https:\/\/doi.org\/10.1097\/MD.0000000000033110.","journal-title":"Med (Baltim)"},{"key":"5160_CR60","doi-asserted-by":"publisher","first-page":"102495","DOI":"10.1016\/j.jceh.2024.102495","volume":"15","author":"M Souza","year":"2025","unstructured":"Souza M, Al-Sharif L, Diaz I, Mantovani A, Villela-Nogueira CA. Global epidemiology and implications of PNPLA3 I148M variant in metabolic dysfunction\u2013associated steatotic liver disease: a systematic review and meta-analysis. J Clin Exp Hepatol. 2025;15:102495. https:\/\/doi.org\/10.1016\/j.jceh.2024.102495.","journal-title":"J Clin Exp Hepatol"},{"key":"5160_CR61","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12920-025-02278-2","volume":"19","author":"S Yang","year":"2026","unstructured":"Yang S, Cheng A. Association between PNPLA3 rs738409 and susceptibility to etiology-specific liver cirrhosis: a systematic review and meta-analysis. BMC Med Genomics. 2026;19:2. https:\/\/doi.org\/10.1186\/s12920-025-02278-2.","journal-title":"BMC Med Genomics"},{"key":"5160_CR62","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3892\/ijmm.2026.5729","volume":"57","author":"X-M Chen","year":"2026","unstructured":"Chen X-M, Liang Y-B, Zuo J-X, Yang Z-S, Zhang L-Y, Zhang X-Y, et al. ZG16B: a key regulator of tumor progression and immune microenvironment modulation in cancer (Review). Int J Mol Med. 2026;57:58. https:\/\/doi.org\/10.3892\/ijmm.2026.5729.","journal-title":"Int J Mol Med"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05160-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05160-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05160-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:02:46Z","timestamp":1792152166000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05160-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5160"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05160-2","relation":{"references":[{"id-type":"doi","id":"10.1053\/j.gastro.2019.11.312","asserted-by":"subject"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"659"}}